Nonlinear Correlation and Mediation Effects Between Serum 25-hydroxyvitamin D Levels and All-cause Mortality in COPD Patients

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Jun 21

PMID 38903612

Authors

Qi Jiang

Yuewen Jiang

Zheru Ma

Jingda Huang

Yang Li

Affiliations

Soon will be listed here.

Abstract

Background: Numerous studies have shown that low levels of vitamin D are linked to a higher risk of inflammatory diseases and their progression. However, how vitamin D levels affect mortality in chronic obstructive pulmonary disease (COPD) patients is still unclear. Thus, this study aimed to explore the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and the risk of death from all causes in U.S. adults with COPD.

Methods: This study analyzed 1,876 adults with COPD from the National Health and Nutrition Examination Survey (2005-2018). Mortality data up to December 31, 2019, were obtained from the National Death Index (NDI) records. Participants were categorized into three groups according to their 25(OH)D levels: Q1 (<50.0 nmol/L) for deficiency; Q2 (50.0-74.9 nmol/L) for insufficiency; and Q3 (≥75.0 nmol/L) for adequacy. A weighted Cox regression model assessed the link between 25(OH)D levels and mortality. Kaplan-Meier survival curves, subgroup, and sensitivity analyses were conducted. Additionally, the relationship between 25(OH)D and the hazard ratio (HR) was detailed through restricted cubic spline analysis. Mediation analysis revealed how 25(OH)D mediates the relationship between Dietary Inflammatory Index and mortality.

Results: There were 395 all-cause deaths during the follow-up, resulting in a mortality rate of 21.06%. After adjusting for potential confounders, higher 25(OH)D levels significantly correlated with a lower risk of all-cause mortality in COPD patients (HR = 0.52, 95% CI: 0.37-0.72, < 0.001). Restricted cubic spline analysis indicated a non-linear relationship between 25(OH)D levels and all-cause mortality ( for nonlinear = 0.023), with levels below 63.4 nmol/L posing an independent risk for all-cause mortality in COPD patients (HR = 0.98, 95% CI: 0.97-0.99, = 0.005). Sensitivity and subgroup analyses confirmed our results' robustness, with mediation analysis showing 25(OH)D's 22% mediating effect on diet-induced inflammation and all-cause mortality in COPD patients.

Conclusion: 25(OH)D independently lowers the risk of all-cause mortality in COPD patients, with a non-linear L-shaped correlation, and mediates the effect of Dietary Inflammatory Index on mortality, suggesting new therapeutic possibilities.

References

Buist A, McBurnie M, Vollmer W, Gillespie S, Burney P, Mannino D . International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589):741-50. DOI: 10.1016/S0140-6736(07)61377-4. View

Barnes P . Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138(1):16-27. DOI: 10.1016/j.jaci.2016.05.011. View

Sundar I, Hwang J, Wu S, Sun J, Rahman I . Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates formation. Biochem Biophys Res Commun. 2011; 406(1):127-33. PMC: 3049841. DOI: 10.1016/j.bbrc.2011.02.011. View

Zhu Z, Wan X, Liu J, Zhang D, Luo P, Du W . Vitamin D status and chronic obstructive pulmonary disease risk: a prospective UK Biobank study. BMJ Open Respir Res. 2023; 10(1). PMC: 10314673. DOI: 10.1136/bmjresp-2023-001684. View

Zendedel A, Gholami M, Anbari K, Ghanadi K, Bachari E, Azargon A . Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study. Glob J Health Sci. 2015; 7(4):243-8. PMC: 4802087. DOI: 10.5539/gjhs.v7n4p243. View

Wang Y, Wang J, Chen L, Zhang H, Yu L, Chi Y . Efficacy of vitamin D supplementation on COPD and asthma control: A systematic review and meta-analysis. J Glob Health. 2022; 12:04100. PMC: 9754066. DOI: 10.7189/jogh.12.04100. View

Shapiro S . Proteolysis in the lung. Eur Respir J Suppl. 2003; 44:30s-32s. DOI: 10.1183/09031936.03.00000903a. View

Persson L, Aanerud M, Hiemstra P, Michelsen A, Ueland T, Hardie J . Vitamin D, vitamin D binding protein, and longitudinal outcomes in COPD. PLoS One. 2015; 10(3):e0121622. PMC: 4372215. DOI: 10.1371/journal.pone.0121622. View

Bikle D . Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep. 2009; 7(2):58-63. DOI: 10.1007/s11914-009-0011-6. View

10.

Alam I, Shivappa N, Hebert J, Pawelec G, Larbi A . Relationships between the inflammatory potential of the diet, aging and anthropometric measurements in a cross-sectional study in Pakistan. Nutr Healthy Aging. 2018; 4(4):335-343. PMC: 6004925. DOI: 10.3233/NHA-180042. View

11.

Ochs-Balcom H, Grant B, Muti P, Sempos C, Freudenheim J, Browne R . Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. Eur J Clin Nutr. 2006; 60(8):991-9. DOI: 10.1038/sj.ejcn.1602410. View

12.

Noyan T, Balaharoglu R, Komuroglu U . The oxidant and antioxidant effects of 25-hydroxyvitamin D3 in liver, kidney and heart tissues of diabetic rats. Clin Exp Med. 2005; 5(1):31-6. DOI: 10.1007/s10238-005-0061-8. View

13.

Alavi Foumani A, Mehrdad M, Jafarinezhad A, Nokani K, Jafari A . Impact of vitamin D on spirometry findings and quality of life in patients with chronic obstructive pulmonary disease: a randomized, double-blinded, placebo-controlled clinical trial. Int J Chron Obstruct Pulmon Dis. 2019; 14:1495-1501. PMC: 6625601. DOI: 10.2147/COPD.S207400. View

14.

Burkes R, Ceppe A, Doerschuk C, Couper D, Hoffman E, Comellas A . Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort. Chest. 2020; 157(4):856-865. PMC: 7118244. DOI: 10.1016/j.chest.2019.11.047. View

15.

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

16.

Ahmad S, Arora S, Khan S, Mohsin M, Mohan A, Manda K . Vitamin D and its therapeutic relevance in pulmonary diseases. J Nutr Biochem. 2021; 90:108571. DOI: 10.1016/j.jnutbio.2020.108571. View

17.

Barnes P . Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014; 35(1):71-86. DOI: 10.1016/j.ccm.2013.10.004. View

18.

Scoditti E, Massaro M, Garbarino S, Toraldo D . Role of Diet in Chronic Obstructive Pulmonary Disease Prevention and Treatment. Nutrients. 2019; 11(6). PMC: 6627281. DOI: 10.3390/nu11061357. View

19.

Alam I, Gul R, Chong J, Tan C, Chin H, Wong G . Recurrent circadian fasting (RCF) improves blood pressure, biomarkers of cardiometabolic risk and regulates inflammation in men. J Transl Med. 2019; 17(1):272. PMC: 6700786. DOI: 10.1186/s12967-019-2007-z. View

20.

Hogg J, Timens W . The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2008; 4:435-59. DOI: 10.1146/annurev.pathol.4.110807.092145. View